The future of pharmacogenetics in the treatment of heart failure.


Heart failure is a common disease with high levels of morbidity and mortality. Current treatment comprises β-blockers, ACE inhibitors, aldosterone antagonists and diuretics. Variation in clinical response seen in patients begs the question of whether there is a pharmacogenetic component yet to be identified. To date, the genes most studied involve the β-1… (More)
DOI: 10.2217/pgs.15.120


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics